PCN72 ECONOMIC EVALUATION OF SUNITINIB VS. INTERFERON-A AND BEVACIZUMAB INTERFERON-A IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (CCRM) - BRAZILIAN PRIVATE HEALTH SYSTEM PERSPECTIVE
Abstract
Authors
V Teich CM Hashizume T Marinho C Charbonneau A Naves